A citation-based method for searching scientific literature

Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews. Diabetes Care 2015
Times Cited: 156



J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
Times Cited: 355




List of shared articles



Times cited

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
3



Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho, Andrei C Sposito. Rev Assoc Med Bras (1992) 2019
9


No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han, Linong Ji. J Diabetes Investig 2018
28

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Xiaoling Cai, Wenjia Yang, Xueying Gao, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji. Obesity (Silver Spring) 2018
46

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
William V Tamborlane, David Polidori, Domenick Argenti, Nicholas A Di Prospero. Pediatr Diabetes 2018
1

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Samuel Seidu, Setor K Kunutsor, Xavier Cos, Syed Gillani, Kamlesh Khunti. Prim Care Diabetes 2018
36

A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes.
Ronald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, Irving S Gottesman, Jean-François Yale. Diabetes Obes Metab 2018
0

SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Radica Z Alicic, Emily J Johnson, Katherine R Tuttle. Am J Kidney Dis 2018
46


Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Rong Qiu, Dainius Balis, John Xie, Michael J Davies, Mehul Desai, Gary Meininger. Curr Med Res Opin 2017
20

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.
Michael J Davies, Katherine W Merton, Ujjwala Vijapurkar, Dainius A Balis, Mehul Desai. Diabetes Metab Syndr Obes 2017
8

Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.
Sanjay Kalra, Sujoy Ghosh, A H Aamir, Md Tofail Ahmed, Mohammod Feroz Amin, Sarita Bajaj, Manash P Baruah, Uditha Bulugahapitiya, A K Das, Mimi Giri,[...]. Indian J Endocrinol Metab 2017
9

The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.
Luca Di Lullo, Michela Mangano, Claudio Ronco, Vincenzo Barbera, Antonio De Pascalis, Antonio Bellasi, Domenico Russo, Biagio Di Iorio, Mario Cozzolino. Diabetes Metab Syndr 2017
9




Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.
Joshua J Neumiller, Radica Z Alicic, Katherine R Tuttle. J Am Soc Nephrol 2017
35



Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim,[...]. Int J Clin Pract 2017
22

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia. Indian J Endocrinol Metab 2017
0

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
G Fulcher, D R Matthews, V Perkovic, D de Zeeuw, K W Mahaffey, C Mathieu, V Woo, C Wysham, G Capuano, M Desai,[...]. Diabetes Obes Metab 2016
52